{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:54:58Z","timestamp":1790891698684,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ucl.2026.06.010","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:23:18Z","timestamp":1784838198000},"page":"635-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New and Novel Agents for Advanced Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Michael","family":"Superdock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopa","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ucl.2026.06.010_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-5347(17)48996-8","article-title":"Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium","volume":"133","author":"Sternberg","year":"1985","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.010_bib2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ucl.2026.06.010_bib3","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ucl.2026.06.010_bib4","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2026.06.010_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.19524","article-title":"Survival trends in urothelial cancer before and after ICIs and antibody drug conjugates","volume":"8","author":"Lian","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.010_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2025.12.018","article-title":"Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice","volume":"44","author":"Squires","year":"2026","journal-title":"Urol Oncol"},{"issue":"10031","key":"10.1016\/j.ucl.2026.06.010_bib7","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.010_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.06.010_bib9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.010_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.010_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ucl.2026.06.010_bib12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2026.06.010_bib13","doi-asserted-by":"crossref","first-page":"S1648","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"LBA2 perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.010_bib14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2026.06.010_bib15","first-page":"TPS4587","article-title":"KEYNOTE-B15\/EV-304: randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC)","volume":"39","author":"Hoimes","year":"2021","journal-title":"J Clin Orthod"},{"issue":"24","key":"10.1016\/j.ucl.2026.06.010_bib16","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.010_bib17","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase i study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.06.010_bib18","doi-asserted-by":"crossref","first-page":"S590","DOI":"10.1016\/j.annonc.2025.08.1532","article-title":"963P SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients (pts) with advanced or metastatic solid tumors: results from dose escalation study","volume":"36","author":"Li","year":"2025","journal-title":"Ann Oncol"},{"issue":"52","key":"10.1016\/j.ucl.2026.06.010_bib19","doi-asserted-by":"crossref","first-page":"12690","DOI":"10.1002\/chem.201702117","article-title":"Bicyclic peptides as next-generation therapeutics","volume":"23","author":"Rhodes","year":"2017","journal-title":"Chemistry"},{"issue":"35","key":"10.1016\/j.ucl.2026.06.010_bib20","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1200\/JCO-25-00559","article-title":"First-in-human, phase I\/II dose escalation and expansion study of zelenectide pevedotin in patients with advanced solid tumors: results from monotherapy dose escalation","volume":"43","author":"Baldini","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.06.010_bib21","doi-asserted-by":"crossref","first-page":"S513","DOI":"10.1016\/j.annonc.2024.08.716","article-title":"650P initial results from a phase I\/II study of BT7480, a novel nectin-4\/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors","volume":"35","author":"Papadopoulos","year":"2024","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.06.010_bib22","first-page":"538","article-title":"HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: associations and clinical outcomes for advanced bladder cancer","volume":"42","author":"Aggen","year":"2024","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.010_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ucl.2026.06.010_bib24","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ucl.2026.06.010_bib25","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/14796694.2025.2535280","article-title":"SGNDV-001: Disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.06.010_bib26","first-page":"TPS594","article-title":"Phase 2 clinical study evaluating the efficacy and safety of Disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001)","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Orthod"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.06.010_bib27","first-page":"665","article-title":"Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: updated efficacy and safety results from the phase II RC48-C017 trial","volume":"43","author":"Sheng","year":"2025","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.06.010_bib28","doi-asserted-by":"crossref","first-page":"S1494","DOI":"10.1016\/j.annonc.2025.08.3699","article-title":"3085P PUNCH02: interim results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients","volume":"36","author":"Huang","year":"2025","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2026.06.010_bib29","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.bjc.6602251","article-title":"Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients","volume":"91","author":"Memon","year":"2004","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.ucl.2026.06.010_bib30","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.3390\/cancers14246174","article-title":"HER3 alterations in cancer and potential clinical implications","volume":"14","author":"Kilroy","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"30","key":"10.1016\/j.ucl.2026.06.010_bib31","doi-asserted-by":"crossref","first-page":"48905","DOI":"10.18632\/oncotarget.16554","article-title":"HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts","volume":"8","author":"Eriksson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2026.06.010_bib32","doi-asserted-by":"crossref","first-page":"S534","DOI":"10.1016\/j.annonc.2024.08.2161","article-title":"690TiP HERTHENA-PanTumor01: a global phase II trial of HER3-DXd in metastatic solid tumors","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"10516","key":"10.1016\/j.ucl.2026.06.010_bib33","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(25)01954-3","article-title":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody\u2013drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China","volume":"406","author":"Yang","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ucl.2026.06.010_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.ucl.2026.06.010_bib35","first-page":"2474","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Orthod"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.010_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.010_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.06.010_bib38","first-page":"TPS4618","article-title":"Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment na\u00efve UC (DAD-IO)","volume":"42","author":"McGregor","year":"2024","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.06.010_bib39","first-page":"4591","article-title":"First survival outcomes and biomarker results of SURE-01: neoadjuvant sacituzumab govitecan (SG) monotherapy, followed by radical cystectomy (RC), in patients with muscle-invasive urothelial bladder cancer (MIBC)","volume":"43","author":"Maiorano","year":"2025","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.06.010_bib40","first-page":"4518","article-title":"First results of SURE-02: a phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC)","volume":"43","author":"Necchi","year":"2025","journal-title":"J Clin Orthod"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.06.010_bib41","first-page":"603","article-title":"Datopotamab deruxtecan in locally advanced\/metastatic urothelial cancer: preliminary results from the phase 1 TROPION-PanTumor01 study","volume":"42","author":"Lisberg","year":"2024","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.06.010_bib42","doi-asserted-by":"crossref","first-page":"S1485","DOI":"10.1016\/j.annonc.2025.08.3686","article-title":"3072MO datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a\/mUC): results from the phase II TROPION-PanTumor03 study","volume":"36","author":"Rha","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.010_bib43","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.annonc.2025.11.013","article-title":"Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors","volume":"37","author":"Zhu","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2026.06.010_bib44","first-page":"59","article-title":"Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies","volume":"8","author":"Hao","year":"2025","journal-title":"Cancer Drug Resist"},{"issue":"32","key":"10.1016\/j.ucl.2026.06.010_bib45","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/JCO-25-00109","article-title":"Efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic urothelial carcinoma: a phase II clinical trial","volume":"43","author":"Bian","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.010_bib46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2024.02.001","article-title":"The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer","volume":"35","author":"Bertucci","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2026.06.010_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2025.04.005","article-title":"Clinical and genomic landscape of FGFR3 alterations across different stages of urothelial cancer","volume":"77","author":"Haas","year":"2025","journal-title":"Eur Urol Open Sci"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.010_bib48","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ucl.2026.06.010_bib49","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.010_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2026.06.010_bib51","author":"Drakaki"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.06.010_bib52","first-page":"662","article-title":"A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: initial results from FORAGER-1","volume":"43","author":"Iyer","year":"2025","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.06.010_bib53","doi-asserted-by":"crossref","unstructured":"Ben Tran. Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations\/fusions (SURF301). Presented at: 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics; October 25, 2024; Barcelona, Spain.","DOI":"10.1016\/j.ejca.2024.114978"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.06.010_bib54","first-page":"TPS4623","volume":"42","author":"Hussain","year":"2024","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.010_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-08157-y","article-title":"Recurrent activating mutations of PPAR\u03b3 associated with luminal bladder tumors","volume":"10","author":"Rochel","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.010_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26421-6","article-title":"Pparg signaling controls bladder cancer subtype and immune exclusion","volume":"12","author":"Tate","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.010_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41467-017-00147-w","article-title":"Evasion of immunosurveillance by genomic alterations of PPAR\u03b3\/RXR\u03b1 in bladder cancer","volume":"8","author":"Korpal","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.010_bib58","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","article-title":"Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience","volume":"125","author":"Rose","year":"2021","journal-title":"Br J Cancer"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2026.06.010_bib59","first-page":"TPS709","article-title":"A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma","volume":"42","author":"Iyer","year":"2024","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.06.010_bib60","unstructured":"Xin Gao. Safety and clinical activity of FX-909, a first-in-class oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), a master regulator of luminal lineage in patients with advanced urothelial carcinoma. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 24, 2025; Boston, Massachusetts."},{"issue":"12","key":"10.1016\/j.ucl.2026.06.010_bib61","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"Van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ucl.2026.06.010_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115731","article-title":"Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: the NABUCCO trial","volume":"229","author":"Stockem","year":"2025","journal-title":"Eur J Cancer"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.06.010_bib63","first-page":"TPS579","article-title":"A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA)","volume":"40","author":"Powles","year":"2022","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.06.010_bib64","doi-asserted-by":"crossref","first-page":"S1140","DOI":"10.1016\/j.annonc.2024.08.2055","article-title":"1970MO Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial","volume":"35","author":"Drakaki","year":"2024","journal-title":"Ann Oncol"},{"issue":"5\u20136","key":"10.1016\/j.ucl.2026.06.010_bib65","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.010_bib66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2026.06.010_bib67","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3389\/fphys.2018.01712","article-title":"GDF15 and growth control","volume":"9","author":"Emmerson","year":"2018","journal-title":"Front Physiol"},{"issue":"8048","key":"10.1016\/j.ucl.2026.06.010_bib68","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ucl.2026.06.010_bib69","doi-asserted-by":"crossref","first-page":"S843","DOI":"10.1016\/j.annonc.2025.08.2144","volume":"36","author":"Melero","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2026.06.010_bib70","doi-asserted-by":"crossref","first-page":"S1651","DOI":"10.1016\/j.annonc.2025.09.129","article-title":"LBA110 A blinded, exploratory phase II trial of nivolumab and the GDF-15 neutralizing antibody visugromab or placebo as neoadjuvant treatment of patients with muscle-invasive bladder cancer (MIBC): primary results of the GDFather-NEO trial","volume":"36","author":"Necchi","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.010_bib71","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2379086","article-title":"Vaccine approaches to treat urothelial cancer","volume":"20","author":"Giudice","year":"2024","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.ucl.2026.06.010_bib72","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002288","article-title":"Neoantigen immunotherapy: a novel treatment for bladder cancer","volume":"6","author":"Lv","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.010_bib73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.010_bib74","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","article-title":"Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial","volume":"6","author":"Saxena","year":"2025","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.010_bib75","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12951-025-03277-2","article-title":"Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?","volume":"23","author":"Wang","year":"2025","journal-title":"J Nanobiotechnology"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2026.06.010_bib76","first-page":"TPS4619","article-title":"A phase 2\/3 study of bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la\/mUC): duravelo-2","volume":"42","author":"Loriot","year":"2024","journal-title":"J Clin Orthod"},{"issue":"33","key":"10.1016\/j.ucl.2026.06.010_bib77","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for bacillus calmette-Gu\u00e9rin\u2013Unresponsive high-risk Non\u2013muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.010_bib79","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S1470-2045(25)00358-4","volume":"26","author":"Necchi","year":"2025","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.06.010_bib80","first-page":"TPS583","volume":"41","author":"Vilaseca","year":"2023","journal-title":"J Clin Orthod"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.06.010_bib81","first-page":"548","article-title":"Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer","volume":"41","author":"Mahmoud","year":"2023","journal-title":"J Clin Orthod"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.010_bib82","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/1535-7163.MCT-15-0570","article-title":"Development of ASG-15ME, a novel antibody\u2013drug conjugate targeting SLITRK6 , a new urothelial cancer biomarker","volume":"15","author":"Morrison","year":"2016","journal-title":"Mol Cancer Therapeut"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:59:41Z","timestamp":1790888381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0094014326000637"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.010","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and Novel Agents for Advanced Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}